Annual Cash & Cash Equivalents
$6.57 M
-$2.34 M-26.27%
June 30, 2024
Summary
- As of March 10, 2025, INM annual cash & cash equivalents is $6.57 million, with the most recent change of -$2.34 million (-26.27%) on June 30, 2024.
- During the last 3 years, INM annual cash & cash equivalents has fallen by -$791.50 thousand (-10.75%).
- INM annual cash & cash equivalents is now -64.19% below its all-time high of $18.35 million, reached on June 30, 2018.
Performance
INM Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$3.42 M
-$2.16 M-38.75%
December 31, 2024
Summary
- As of March 10, 2025, INM quarterly cash and cash equivalents is $3.42 million, with the most recent change of -$2.16 million (-38.75%) on December 31, 2024.
- Over the past year, INM quarterly cash and cash equivalents has stayed the same.
- INM quarterly cash and cash equivalents is now -81.37% below its all-time high of $18.35 million, reached on June 30, 2018.
Performance
INM Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
INM Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -26.3% | 0.0% |
| 3 y3 years | -10.8% | 0.0% |
| 5 y5 years | -33.0% | 0.0% |
INM Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -26.3% | +6.4% | -70.1% | at low |
| 5 y | 5-year | -33.0% | +13.2% | -77.7% | at low |
| alltime | all time | -64.2% | -100.0% | -81.4% | -100.0% |
InMed Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $3.42 M(-38.8%) |
| Sep 2024 | - | $5.58 M(-15.0%) |
| Jun 2024 | $6.57 M(-26.3%) | $6.57 M(-13.5%) |
| Mar 2024 | - | $7.60 M(-20.3%) |
| Dec 2023 | - | $9.53 M(+41.5%) |
| Sep 2023 | - | $6.74 M(-24.4%) |
| Jun 2023 | $8.91 M(+44.3%) | $8.91 M(-7.2%) |
| Mar 2023 | - | $9.60 M(-16.1%) |
| Dec 2022 | - | $11.45 M(+22.5%) |
| Sep 2022 | - | $9.35 M(+51.4%) |
| Jun 2022 | $6.18 M(-16.1%) | $6.18 M(+4.7%) |
| Mar 2022 | - | $5.90 M(-47.7%) |
| Dec 2021 | - | $11.28 M(-26.5%) |
| Sep 2021 | - | $15.34 M(+108.4%) |
| Jun 2021 | $7.36 M(+26.8%) | $7.36 M(-22.1%) |
| Mar 2021 | - | $9.45 M(-5.7%) |
| Dec 2020 | - | $10.02 M(+122.8%) |
| Sep 2020 | - | $4.50 M(-22.5%) |
| Jun 2020 | $5.81 M(-40.8%) | $5.81 M(-16.7%) |
| Mar 2020 | - | $6.97 M(-23.8%) |
| Dec 2019 | - | $9.15 M(-17.7%) |
| Sep 2019 | - | $11.11 M(+13.3%) |
| Jun 2019 | $9.81 M(-46.6%) | $9.81 M(+1.3%) |
| Mar 2019 | - | $9.68 M(-15.0%) |
| Dec 2018 | - | $11.40 M(-15.3%) |
| Sep 2018 | - | $13.46 M(-26.6%) |
| Jun 2018 | $18.35 M(+255.8%) | $18.35 M(+105.2%) |
| Mar 2018 | - | $8.94 M(-13.3%) |
| Dec 2017 | - | $10.31 M(+112.1%) |
| Sep 2017 | - | $4.86 M(-5.7%) |
| Jun 2017 | $5.16 M(>+9900.0%) | $5.16 M(+151.7%) |
| Mar 2017 | - | $2.05 M(+288.5%) |
| Dec 2016 | - | $527.40 K(+313.3%) |
| Sep 2016 | - | $127.60 K(+204.5%) |
| Jun 2016 | $41.90 K(-68.8%) | $41.90 K(+451.3%) |
| Mar 2016 | - | $7600.00(-75.6%) |
| Dec 2015 | - | $31.10 K(+658.5%) |
| Sep 2015 | - | $4100.00(-96.9%) |
| Jun 2015 | $134.20 K(+1790.1%) | $134.20 K(+232.2%) |
| Mar 2015 | - | $40.40 K(+37.4%) |
| Dec 2014 | - | $29.40 K(+263.0%) |
| Sep 2014 | - | $8100.00(+14.1%) |
| Jun 2014 | $7100.00 | $7100.00(+446.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $1300.00(+44.4%) |
| Dec 2013 | - | $900.00(-35.7%) |
| Sep 2013 | - | $1400.00(-65.9%) |
| Jun 2013 | $4100.00(-90.9%) | $4100.00(+86.4%) |
| Mar 2013 | - | $2200.00(-4.3%) |
| Dec 2012 | - | $2300.00(-87.6%) |
| Sep 2012 | - | $18.50 K(-58.8%) |
| Jun 2012 | $44.90 K(-80.5%) | $44.90 K(-49.7%) |
| Mar 2012 | - | $89.30 K(-12.9%) |
| Dec 2011 | - | $102.50 K(-41.5%) |
| Sep 2011 | - | $175.10 K(-24.0%) |
| Jun 2011 | $230.50 K(>+9900.0%) | $230.50 K(-61.0%) |
| Mar 2011 | - | $591.20 K(>+9900.0%) |
| Jun 2010 | $0.00(-100.0%) | $0.00(0.0%) |
| Mar 2009 | - | $0.00(-100.0%) |
| Dec 2008 | - | $2100.00(+600.0%) |
| Sep 2008 | - | $300.00(-99.4%) |
| Jun 2008 | $46.80 K(-63.4%) | $46.80 K(-55.7%) |
| Mar 2008 | - | $105.70 K(-53.1%) |
| Dec 2007 | - | $225.50 K(+47.9%) |
| Sep 2007 | - | $152.50 K(+19.3%) |
| Jun 2007 | $127.80 K(+170.2%) | $127.80 K(-59.5%) |
| Mar 2007 | - | $315.50 K(+1214.6%) |
| Dec 2006 | - | $24.00 K(+238.0%) |
| Sep 2006 | - | $7100.00(-85.0%) |
| Jun 2006 | $47.30 K(+228.5%) | $47.30 K(+1251.4%) |
| Mar 2006 | - | $3500.00(-80.9%) |
| Dec 2005 | - | $18.30 K(-29.6%) |
| Sep 2005 | - | $26.00 K(-49.7%) |
| Dec 2004 | - | $51.70 K(+91.5%) |
| Sep 2004 | - | $27.00 K(+87.5%) |
| Jul 2004 | $14.40 K(-70.7%) | $14.40 K(-48.4%) |
| Apr 2004 | - | $27.90 K(+18.7%) |
| Jan 2004 | - | $23.50 K(-71.1%) |
| Oct 2003 | - | $81.30 K(+65.6%) |
| Jul 2003 | $49.10 K(+1263.9%) | $49.10 K(+154.4%) |
| Apr 2003 | - | $19.30 K(+26.1%) |
| Jan 2003 | - | $15.30 K(-47.2%) |
| Oct 2002 | - | $29.00 K(+705.6%) |
| Jul 2002 | $3600.00(-91.2%) | $3600.00(-83.0%) |
| Apr 2002 | - | $21.20 K(+21.1%) |
| Jan 2002 | - | $17.50 K(+1844.4%) |
| Oct 2001 | - | $900.00 |
| Jul 2001 | $41.00 K | - |
FAQ
- What is InMed Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is InMed Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for InMed Pharmaceuticals?
- What is InMed Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is InMed Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of INM is $6.57 M
What is the all time high annual cash & cash equivalents for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high annual cash & cash equivalents is $18.35 M
What is InMed Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, INM annual cash & cash equivalents has changed by -$2.34 M (-26.27%)
What is InMed Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of INM is $3.42 M
What is the all time high quarterly cash and cash equivalents for InMed Pharmaceuticals?
InMed Pharmaceuticals all-time high quarterly cash and cash equivalents is $18.35 M
What is InMed Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, INM quarterly cash and cash equivalents has changed by $0.00 (0.00%)